ArticleJournal of advanced research2026
Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute lymphoblastic leukemia (ALL) is a highly heterogeneous hematologic malignancy with poor prognosis in refractory and relapsed cases. Aurora kinase B (AURKB), a member of the Aurora kinase family, is markedly overexpressed in ALL patients with cytogenetic abnormalities and is associated with unfavorable clinical outcomes. Targeting AURKB represents a promising therapeutic approach to address this unmet clinical need.
objectivesThis study aimed to develop and validate a novel, selective degradation strategy against AURKB in ALL, utilizing artificial intelligence-assisted drug design to create a peptide-based degrader. The goal was to demonstrate the efficacy of this degrader in reducing AURKB expression and suppressing leukemic cell growth.
methodsWe performed database analyses and confirmed AURKB overexpression in patient-derived ALL samples. Using AI-assisted design, we developed ATPD (AURKB Targeting Peptide Degrader), a selective peptide-based degrader of AURKB. The activity of ATPD was evaluated through in vitro cell proliferation assays, in vivo leukemia models, and ex vivo cytotoxicity tests using primary ALL cells.
resultsATPD effectively induced the degradation of AURKB and significantly inhibited the proliferation of ALL cells both in vitro and in vivo. Furthermore, ATPD exhibited potent cytotoxic activity against primary leukemic cells derived from ALL patients, B-All PDX, and mini-PDX models.
conclusionOur findings demonstrate that ATPD is the first AI-designed, selective AURKB degrader with potent anti-leukemic activity. This study highlights ATPD's potential as a novel, precise therapeutic strategy for the treatment of ALL, addressing a critical gap in managing refractory and relapsed disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.